Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Pulmatrix (PULM) stocks

Learn how to easily invest in Pulmatrix stocks.

Pulmatrix is a biotechnology business based in the US. Pulmatrix stocks (PULM.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.948 – an increase of 6.59% over the previous week. Pulmatrix employs 24 staff and has a trailing 12-month revenue of around $4.9 million.

How to buy stocks in Pulmatrix

  1. Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PULM – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Pulmatrix stock price (NASDAQ:PULM)

Use our graph to track the performance of PULM stocks over time.

Pulmatrix shares at a glance

Information last updated 2022-06-24.
Latest market close$4.69
52-week range$4.03 - $22.00
50-day moving average $5.18
200-day moving average $9.49
Wall St. target price$10.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-8.20

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 6 of 6
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95–$6.95
$0 if conditions met, otherwise $100 a year
Stocks, Bonds, Options, Mutual Funds, ETFs
Young investors 18 to 24 can get free online trades and a $0 annual account fee. Conditions apply.
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99–$9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
FREE TRADES
Wealthsimple
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get $25 when you open a Wealthsimple account and fund at least $150.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
OFFER
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get almost $500 in commission free trades when you fund your new account with a minimum of $10,000. Conditions apply. Ends August 31, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Pulmatrix stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Pulmatrix price performance over time

Historical closes compared with the close of $4.69 from 2022-06-27

1 week (2022-06-21) 6.59%
1 month (2022-05-25) -6.25%
3 months (2022-03-28) -27.51%
6 months (2021-12-24) N/A
1 year (2021-06-28) 326.36%
2 years (2020-06-26) 149.47%
3 years (2019-06-28) 408.73%
5 years (2017-06-28) 93.00%

Pulmatrix financials

Revenue TTM $4.9 million
Gross profit TTM $5.2 million
Return on assets TTM -17.59%
Return on equity TTM -42.33%
Profit margin 0%
Book value $12.75
Market capitalisation $15.5 million

TTM: trailing 12 months

Pulmatrix share dividends

We're not expecting Pulmatrix to pay a dividend over the next 12 months.

Have Pulmatrix's shares ever split?

Pulmatrix's shares were split on a 1:20 basis on 1 March 2022. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Pulmatrix shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Pulmatrix shares which in turn could have impacted Pulmatrix's share price.

Pulmatrix share price volatility

Over the last 12 months, Pulmatrix's shares have ranged in value from as little as $4.032 up to $22. A popular way to gauge a stock's volatility is its "beta".

PULM.US volatility(beta: 1.12)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pulmatrix's is 1.1175. This would suggest that Pulmatrix's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Pulmatrix overview

Pulmatrix, Inc. , a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc.

Frequently asked questions


Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site